Navigation Links
IDM Pharma Announces IDM-2101 Updated Phase 2 Results Show Treatment Well Tolerated With Positive Survival Trend in Lung Cancer Patients
Date:11/2/2007

, and an estimated 160,000 patients will die from lung cancer. The American Cancer Society also estimates that non-small cell lung cancer represents 87 percent of all lung cancers.

In the European Union, non-small cell lung cancer represents 75 percent of all lung cancer. In addition, approximately 130,000 new cases will be diagnosed in 2007 in the top five markets (France, Germany, Italy, UK & Spain)

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

For more information about the company and its products, visit http://www.idm-pharma.com.

Forward-Looking Statements

This press release includes and the presentation described in this press release will include forward-looking statements that reflect management's current views of future events including statements regarding the Phase 2 IDM-2101 study, the support that the survival data and positive safety profile and immunological data from the Phase 2 IDM-2101 provides for further clinical evaluation of IDM-2101, and the potential for IDM-2101 as a treatment for non-small cell lung cancer. Actual results may differ materially from the forward-looking statements due to a number of important factors, including, but not limited to, whether the Company or any of its collaborators will be able to develop pharmaceutical products using the technologies of the Company, whether clinical trial results to date are predictive of results of any future clinical trials, risks associated with completing clinical trials of product candidates, risks involved in the regulatory
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Antigen Discovery Inc. (ADi), a privately held company ... receipt of a National Institutes of Health (NIH) Phase ... of Dental and Craniofacial Research (NIDCR). The one-year $225,000 ... Microarray Chip, which will contain every protein in all ... the development of safe and effective vaccines and therapies ...
(Date:10/22/2014)... 2014  Paper Pak Industries, a manufacturer of ... Body Guard Bio, a disposable, highly absorbent ... and virus while protecting service providers and the ... a rugged, external nylon shell, watertight zipper, thermal ... inner chamber that contains contaminated and potentially contagious ...
(Date:10/22/2014)... 2014  With a vision to ensure safety ... Global Pharmaceutical and Biotech manufacturer selects and implements ... solution to protect their animal health brand.  ... Photo - http://photos.prnewswire.com/prnh/20141021/153439 ... aggregated by the Xyntek and Antares solution is ...
Breaking Medicine Technology:Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Xyntek and Antares Serialization Solution Protects Pets Too! 2
... 2011 Healthpoint today announced the launch of a ... Biotherapeutics, along with an updated brandmark and corporate tagline, ... is designed to communicate the company,s commitment to scientific ... contribute to improved outcomes and quality of life for ...
... Md., Feb. 23, 2011 The Cystic Fibrosis Foundation and ... development that targets the defective protein that causes cystic fibrosis, ... The trial was designed to evaluate patients age ... a CF mutation called G551D. The study included 161 patients ...
Cached Medicine Technology:Healthpoint Launches New Corporate Identity 2Healthpoint Launches New Corporate Identity 3Phase 3 Study of VX-770 Shows Marked Improvement in Lung Function Among People with Cystic Fibrosis with G551D Mutation 2Phase 3 Study of VX-770 Shows Marked Improvement in Lung Function Among People with Cystic Fibrosis with G551D Mutation 3
(Date:10/25/2014)... WA (PRWEB) October 25, 2014 Homeowners ... insulation has ‘gone bad’ need wonder no more. Clean ... that homeowners should watch out for when it comes ... insulation, according to the article released by Clean Crawls, ... for homeowners that any insulation that has deteriorated, become ...
(Date:10/25/2014)... Raleigh, NC (PRWEB) October 25, 2014 ... patient who continued to receive pemetrexed (Alimta), after his ... to read the full story , just posted on ... study from Uji Tokushukai Medical Center in Japan suggests ... for mesothelioma patients who cannot tolerate higher ...
(Date:10/25/2014)... -- Interrupting blood supply to an arm or a leg ... the surgery, according to a new study. "During ... the heart to be able to operate on it. After ... ability to produce energy because it doesn,t get oxygen. When ... such as an arm or a leg, the body prepares ...
(Date:10/25/2014)... Not getting the right amount of sleep might raise ... Those who sleep less or more than the ... more prone to developing the chronic condition, which causes ... concluded that duration and quality of sleep are key ... diseases. "Both short and long durations of sleep ...
(Date:10/25/2014)... 23, 2014 (HealthDay News) -- A large influx of ... is to avoid tens of thousands of deaths from ... researchers predict. Using a specially designed mathematical ... the outbreak in just one densely populated county of ... city of Monrovia. The researchers said that if ...
Breaking Medicine News(10 mins):Health News:5 Signs Indicating That Insulation Needs Replacing as Told By Clean Crawls in Recent Article 2Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2
... Despite initiatives, level of diversity among faculty, practitioners still ... say , ANN ARBOR, Mich. , Jan. ... medical school faculty remains low, even as the U.S. population ... currently being trained in medicine is unlikely to reverse those ...
... , Jan. 28 PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ... in 2010. Each of the dividends will be $0.50 per share. ... to all stockholders who own shares of PDL on March 15, 2010 ... October 1, 2010 to all stockholders who own shares of PDL on ...
... , ... of Hematology (ASH) now offers physicians who diagnose and treat ... (CME) credits while staying abreast of the latest clinical strategies ... with Medscape, an online network of medical content for physicians ...
... , BRIGHTON, Mich. , ... alcohol and drug treatment provider in North America, has signed a ... a Saudi Arabian company to build a 291,000 square-foot, 250 ... the entire Islamic Mideast. , Brighton Hospital, the Addiction Treatment ...
... for ovarian cancer does not appear to detect early-stage ovarian ... 1 out of 100 women in the general population with ... in the Journal of the National Cancer Institute . ... in Seattle assessed the predictive value of certain symptoms, including ...
... vaccine developed using non-infectious virus-like particles (VLP) has ... mosquito-borne pathogen that has infected millions of people ... researchers at the National Institutes of Health have ... Allergy and Infectious Diseases (NIAID) developed the vaccine ...
Cached Medicine News:Health News:More Recruiting of Underrepresented Minorities Needed at U.S. Medical Schools, Study Says 2Health News:More Recruiting of Underrepresented Minorities Needed at U.S. Medical Schools, Study Says 3Health News:PDL BioPharma Announces Two $0.50 Dividends in 2010 2Health News:Hematologists Can Now Earn CME Credits Through the Journal Blood 2Health News:Hematologists Can Now Earn CME Credits Through the Journal Blood 3Health News:St. John Health System Brighton Hospital Signs Letter of Intent to Assist Saudi Arabia in Developing New Addiction Treatment Hospital in Riyadh 2Health News:St. John Health System Brighton Hospital Signs Letter of Intent to Assist Saudi Arabia in Developing New Addiction Treatment Hospital in Riyadh 3Health News:St. John Health System Brighton Hospital Signs Letter of Intent to Assist Saudi Arabia in Developing New Addiction Treatment Hospital in Riyadh 4Health News:Symptoms have little value for early detection of ovarian cancer 2Health News:Virus-like particle vaccine protects monkeys from chikungunya virus 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: